Eagle Health Investments LP Acquires 111,191 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Eagle Health Investments LP raised its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 107.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 214,291 shares of the company’s stock after purchasing an additional 111,191 shares during the period. Centessa Pharmaceuticals accounts for about 1.5% of Eagle Health Investments LP’s portfolio, making the stock its 21st largest position. Eagle Health Investments LP’s holdings in Centessa Pharmaceuticals were worth $8,512,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Avoro Capital Advisors LLC lifted its position in shares of Centessa Pharmaceuticals by 34.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after purchasing an additional 3,747,475 shares during the period. EcoR1 Capital LLC increased its holdings in Centessa Pharmaceuticals by 466.4% during the fourth quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after buying an additional 2,565,000 shares during the period. Braidwell LP bought a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $54,730,000. Maverick Capital Ltd. bought a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $41,110,000. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in Centessa Pharmaceuticals by 20.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after buying an additional 1,449,000 shares during the period. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock opened at $40.50 on Tuesday. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $12.74 and a fifty-two week high of $40.56. The firm has a market capitalization of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The stock’s 50-day simple moving average is $40.16 and its 200-day simple moving average is $33.89.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

CNTA has been the topic of a number of analyst reports. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $35.00 to $42.00 in a report on Monday, April 20th. Guggenheim cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Needham & Company LLC downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.